Guidelines for the detection and treatment of osteoporosis;Smernice za odkrivanje in zdravljenje osteoporoze

Zdravniski Vestnik

Volumn 82, Issue 4, 2013, Pages 207-217

  Kocjan, Tomaž ^a   Preželj, Janez ^a   Pfeifer, Marija ^a   Jensterle Sever, Mojca ^a   Čokolič, Miro ^b   Zavratnik, Andrej ^b  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

Author keywords

Bisphosphonates; Calcium; Osteoporotic fractures; Vitamin D

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; ESTROGEN; PARATHYROID HORMONE[1-34]; RALOXIFENE; STRONTIUM RANELATE; VITAMIN D;

ALCOHOL CONSUMPTION; ARTICLE; BONE DENSITY; BONE TURNOVER; DIET; DRUG CHOICE; DRUG EFFECT; EXERCISE; FALLING; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; LIFESTYLE; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PRACTICE GUIDELINE; SMOKING; SPINE FRACTURE;

EID: 84877902221     PISSN: 13180347     EISSN: 15810224     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Ström O, Borgström F, Kanis JA, Compston J, Cooper C, McCloskey EV, et al. Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2011; 6: 59-155.
2. Genant HK, Engelke K, Fuerst T, Glüer CC, Grampp S, Harris ST, et al. Noninvasive assessment of bone mineral and structure: state of the art. J. Bone Miner Res. 1996; 11: 707-30.
3. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J. Bone Miner Res. 1994; 9: 1137-41.
4. Kocijancic A. Smernice za odkrivanje in zdravljenje osteoporoze. Zdrav Vestn. 2002; 71: 571-3.
5. Siris ES, Chen Y-T, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004; 164: 1108-12.
6. Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, et al. Assessment of fracture risk. Osteoporos Int. 2005; 16: 581-9.
7. Siris ES, Boonen S, Mitchell PJ, Bilezikian J, Silverman S. What's in a name? What constitutes the clinical diagnosis of osteoporosis? Osteoporos Int. 2012; 23: 2093-7.
8. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster J-Y, Borgstrom F, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008; 19: 399-428.
9. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J-Y. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013; 24: 23-57.
10. DVO E.V. Guideline 2009 for Prevention, Diagnosis and Therapy of Osteoporosis in Adults. Osteologie. 2011; 20: 55-74.
11. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. Canadian Medical Association Journal. 2010; 182: 1864-73.
12. Dawson-Hughes B. A revised clinician's guide to the prevention and treatment of osteoporosis. J. Clin Endocrinol Metab. 2008; 93: 2463-5.
13. Blake GM, Fogelman I. The clinical role of dual energy X-ray absorptiometry. Eur J Radiol. 2009; 71: 406-14.
14. Preželj J, Kocjan T, Pfeifer M, Sabati Rajić A. Kvaliteta kosti-dejavnik tveganja za zlom. Isis. 2009; 18: 57-8.
15. Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, et al. Interpretation and use of FRAX in clinical practice. Osteoporos Int. 2011; 22: 2395-411.
16. Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA. Does osteoporosis therapy invalidate FRAX for fracture prediction? J Bone Miner Res. 2012; 27: 1243-51.
17. Lewiecki EM, Laster AJ, Miller PD, Bilezikian JP. More bone density testing is needed, not less. J Bone Miner Res. 2012; 27: 739-42.
18. Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012; 97: 1802-22.
19. Hannan MT, Tucker KL, Dawson-Hughes B, Cupples LA, Felson DT, Kiel DP. Effect of dietary protein on bone loss in elderly men and women: the Framingham Osteoporosis Study. J Bone Miner Res. 2000; 15: 2504-12.
20. Rizzoli R. Nutrition: its role in bone health. Best Pract Res Clin Endocrinol Metab. 2008; 22: 813-29.
21. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, Orav JE, Stuck AE, Theiler R, et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ. 2009; 339: b3692.
22. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005; 293: 2257-64.
23. Preželj J, Pfeifer M, Kocjan T, Sabati Rajić A, Gantar Rott U, Jensterle Sever M, et al. Novosti o vitaminu D in kalciju v zdravljenju osteoporoze. Isis. 2008; 17: 74-5.
24. Dawson-Hughes B, Mithal A, Bonjour J-P, Boonen S, Burckhardt P, Fuleihan GE-H, et al. IOF position statement: vitamin D recommendations for older adults. Osteoporos Int. 2010; 21: 1151-4.
25. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96: 1911-30.
26. LaClair RE, Hellman RN, Karp SL, Kraus M, Ofner S, Li Q, et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis. 2005; 45: 1026-33.
27. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011; 96: 53-8.
28. Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ. 2010; 341: c3691.
29. Lewis JR, Calver J, Zhu K, Flicker L, Prince RL. Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up. J Bone Miner Res. 2011; 26: 35-41.
30. Rejnmark L, Avenell A, Masud T, Anderson F, Meyer HE, Sanders KM, et al. Vitamin D with Calcium Reduces Mortality: Patient Level Pooled Analysis of 70,528 Patients from Eight Major Vitamin D Trials. J Clin Endocrinol Metab. 2012; 97: 2670-81.
31. Reid IR, Bolland MJ, Grey A. Effect of calcium supplementation on hip fractures. Osteoporos Int. 2008; 19: 1119-23.
32. Russell RGG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci. 2007; 1117: 209-57.
33. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348: 1535-41.
34. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000; 85: 4118-24.
35. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999; 282: 1344-52.
36. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000; 11: 83-91.
37. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001; 344: 333-40.
38. Chesnut III CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004; 19: 1241-9.
39. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356: 1809-22.
40. Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007; 357: 1799-809.
41. Rizzoli R, Reginster J-Y, Boonen S, Bréart G, Diez- Perez A, Felsenberg D, et al. Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int. 2011; 89: 91-104.
42. Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, et al. Benefits and Risks of Bisphosphonate Therapy for Osteoporosis. J Clin Endocrinol Metab. 2012; 97: 2272-82.
43. Ruggiero SL, Mehrotra B. Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management. Annu Rev Med. 2009; 60: 85-96.
44. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochan teric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010; 25: 2267-94.
45. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003; 290: 1729-38.
46. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SAA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004; 291: 1701-12.
47. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288: 321-33.
48. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007; 297: 1465-77.
49. Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012; 345: e6409.
50. Kocjan T, Franić D. Osteoporoza in hormonsko nadomestno zdravljenje. Zdrav Vestn. 2008; 77(SIII): III43-6.
51. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999; 282: 637-45.
52. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999; 281: 2189-97.
53. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004; 96: 1751-61.
54. Grady D, Ettinger B, Moscarelli E, Plouffe L Jr, Sarkar S, Ciaccia A, et al. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol. 2004; 104: 837-44.
55. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006; 355: 125-37.
56. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361: 756-65.
57. Ferrari-Lacraz S, Ferrari S. Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos Int. 2011; 22: 435-46.
58. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361: 756-65.
59. Papapoulos S, Chapurlat R, Libanati C, Brandi M, Brown J, Czerwiński E, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012; 27: 694-701.
60. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res. 2003; 18: 1932-41.
61. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344: 1434-41.
62. Marie PJ, Ammann P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int. 2001; 69: 121-9.
63. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004; 350: 459-68.
64. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005; 90: 2816-22.
65. Ringe JD, Dorst A, Farahmand P. Efficacy of strontium ranelate on bone mineral density in men with osteoporosis. Arzneimittelforschung. 2010; 60: 267-72.
66. Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S, et al. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res. 2008; 23: 1591-600.
67. Cooper C, Reginster J-Y, Cortet B, Diaz-Curiel M, Lorenc RS, Kanis JA, et al. Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF). Curr Med Res Opin. 2012; 28: 475-91.
68. Boonen S, Ferrari S, Miller PD, Eriksen EF, Sambrook PN, Compston J, et al. Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk-a perspective. J Bone Miner Res. 2012; 27: 963-74.
69. Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab. 2010; 95: 1555-65.
70. Favus MJ. Bisphosphonates for osteoporosis. N Engl J Med. 2010; 363: 2027-35.
71. Kocjan T, Gantar Rott U, Pfeifer M, Preželj J. Neuspešno zdravljenje osteoporoze-kaj lahko storimo? Isis. 2007; 16: 100-2.
72. Diez-Perez A, Adachi JD, Agnusdei D, Bilezikian JP, Compston JE, Cummings SR, et al. Treatment failure in osteoporosis. Osteoporos Int. 2012; 23: 2769-74.